Related Experiment Video
Updated: Oct 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol
1School of Pharmacy, University of Missouri-Kansas City, 64110-2499, USA.
Abstract:
Bile acid sequestrants, fibric acid derivatives (fibrates), hydroxy-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors ("statins"), and niacin are able to increase HDL-C serum concentrations to varying degrees. Bile acid sequestrants are the least effective, whereas niacin is the most powerful agent for increasing HDL-C levels. Because of 2 alternate metabolic pathways of niacin breakdown, flushing or hepatotoxicity can occur in patients taking niacin. These effects can be mediated in a carefully designed formulation of niacin that releases the drug at a predictable rate. Niacin has few drug interactions and is a relatively inexpensive means of increasing HDL-C. A combination formulation that combines niacin plus a statin has shown promise in ongoing clinical trials.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis III: Management
Pharmacokinetics: Drug–Drug Interactions
Coronary Artery Disease IV: Preventive Measures
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
